期刊文献+

Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer 被引量:10

Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer
下载PDF
导出
摘要 AIM:To characterize the implications of vascular endothelial growth factor(VEGF)-A in stromal cells and colorectal cancer and the expression of VEGF-A splice variants.METHODS:VEGF-A expression in tumor and stromal cells from 165 consecutive patients with colorectal cancer was examined by immunohistochemistry.The association between VEGF-A expression status and clinicopathological factors was investigated.Twenty freshfrozen samples were obtained for laser capture microdissection to analyze the splice variants of VEGF-A.RESULTS:VEGF-A was expressed in 53.9% and 42.4% of tumor and stromal cells,respectively.VEGF-A expression in tumor cells(t-VEGF-A) was associated with advanced clinical stage(stage 0,1/9;stage 1,2/16;stage 2,32/55;stage 3,38/66;stage 4,16/19,P < 0.0001).VEGF-A expression in stromal cells(s-VEGF-A) increased in the earlier clinical stage(stage 0,7/9;stage 1,6/16;stage 2,33/55;stage 3,22/66;stage 4,5/19;P = 0.004).Multivariate analyses for risk factors of recurrence showed that only s-VEGF-A expression was an independent risk factor for recurrence(relative risk 0.309,95% confidence interval 0.141-0.676,P = 0.0033).The five-year disease-free survival(DFS) rates of t-VEGF-A-positive and-negative cases were 51.4% and 62.9%,respectively.There was no significant difference in t-VEGF-A expression status.The five-year DFS rates of s-VEGF-A-positive and-negative cases were 73.8% and 39.9%,respectively.s-VEGFA-positive cases had significantly better survival than s-VEGF-A-negative cases(P = 0.0005).Splice variant analysis revealed that t-VEGF-A was mainly composed of VEGF165 and that s-VEGF-A included both VEGF165 and VEGF165b.In cases with no venous invasion(v0),the level of VEGF165b mRNA was significantly higher(v0 204.5 ± 122.7,v1 32.5 ± 36.7,v2 2.1 ± 1.7,P = 0.03).The microvessel density tended to be lower in cases with higher VEGF165b mRNA levels.CONCLUSION:s-VEGF-A appears be a good prognostic factor for colorectal cancer and includes VEGF165 and VEGF165b. AIM:To characterize the implications of vascular endothelial growth factor(VEGF)-A in stromal cells and colorectal cancer and the expression of VEGF-A splice variants.METHODS:VEGF-A expression in tumor and stromal cells from 165 consecutive patients with colorectal cancer was examined by immunohistochemistry.The association between VEGF-A expression status and clinicopathological factors was investigated.Twenty freshfrozen samples were obtained for laser capture microdissection to analyze the splice variants of VEGF-A.RESULTS:VEGF-A was expressed in 53.9% and 42.4% of tumor and stromal cells,respectively.VEGF-A expression in tumor cells(t-VEGF-A) was associated with advanced clinical stage(stage 0,1/9;stage 1,2/16;stage 2,32/55;stage 3,38/66;stage 4,16/19,P 〈 0.0001).VEGF-A expression in stromal cells(s-VEGF-A) increased in the earlier clinical stage(stage 0,7/9;stage 1,6/16;stage 2,33/55;stage 3,22/66;stage 4,5/19;P = 0.004).Multivariate analyses for risk factors of recurrence showed that only s-VEGF-A expression was an independent risk factor for recurrence(relative risk 0.309,95% confidence interval 0.141-0.676,P = 0.0033).The five-year disease-free survival(DFS) rates of t-VEGF-A-positive and-negative cases were 51.4% and 62.9%,respectively.There was no significant difference in t-VEGF-A expression status.The five-year DFS rates of s-VEGF-A-positive and-negative cases were 73.8% and 39.9%,respectively.s-VEGFA-positive cases had significantly better survival than s-VEGF-A-negative cases(P = 0.0005).Splice variant analysis revealed that t-VEGF-A was mainly composed of VEGF165 and that s-VEGF-A included both VEGF165 and VEGF165b.In cases with no venous invasion(v0),the level of VEGF165b mRNA was significantly higher(v0 204.5 ± 122.7,v1 32.5 ± 36.7,v2 2.1 ± 1.7,P = 0.03).The microvessel density tended to be lower in cases with higher VEGF165b mRNA levels.CONCLUSION:s-VEGF-A appears be a good prognostic factor for colorectal cancer and includes VEGF165 and VEGF165b.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第44期4867-4874,共8页 世界胃肠病学杂志(英文版)
关键词 Colorectal cancer Vascular endothelial growth factor-A Vascular endothelial growth factor 165 Microvascular density Stromal cell 血管内皮生长因子 基质细胞 大肠癌 激光捕获显微切割 mRNA水平 免疫组化检测 肿瘤细胞 危险因素
  • 相关文献

参考文献3

二级参考文献127

  • 1[1]Cancer facts and figures 2006.Atlanta:American Cancer Society,2006.Available URL from:http://www.cancer.org/ downloads/STT/CAFF2006PWSecured.pdf
  • 2[2]Obrand DI,Gordon PH.Incidence and patterns of recurrence following curative resection for colorectal carcinoma.Dis Colon Rectum 1997; 40:15-24
  • 3[3]Petrelli N,Douglass HO Jr,Herrera L,Russell D,Stablein DM,Bruckner HW,Mayer RJ,Schinella R,Green MD,Muggia FM.The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma:a prospective randomized phase Ⅲ trial.Gastrointestinal Tumor Study Group.J Clin Oncol 1989; 7:1419-1426
  • 4[4]Poon MA,O'Connell MJ,Moertel CG,Wieand HS,Cullinan SA,Everson LK,Krook JE,Mailliard JA,Laurie JA,Tschetter LK.Biochemical modulation of fluorouracil:evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.J Clin Oncol 1989;7:1407-1418
  • 5[5]Piedbois P,Buyse M,Rustum Y,Machover D,Erlichman C,Carlson R,Valone F,Labianca R,Doroshow J,Petrelli N.Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer:evidence in terms of response rate.
  • 6[6]Advanced Colorectal Cancer Meta-Analysis Project.J Clin Oncol 1992; 10:896-903de Gramont A,Figer A,Seymour M,Homerin M,Hmissi A,Cassidy J,Boni C,Cortes-Funes H,Cervantes A,Freyer G,Papamichael D,Le Bail N,Louvet C,Hendler D,de Braud F,Wilson C,Morvan F,Bonetti A.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol 2000; 18:2938-2947
  • 7[7]Douillard JY,Cunningham D,Roth AD,Navarro M,James RD,Karasek P,Jandik P,Iveson T,Carmichael J,Alakl M,Gruia G,Awad L,Rougier P.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer:a multicentre randomised trial.Lancet 2000; 355:1041-1047
  • 8[8]Goldberg RM,Sargent DJ,Morton RF,Fuchs CS,Ramanathan RK,Williamson SK,Findlay BP,Pitot HC,Alberts SR.A randomized controlled trial of fluorouracil plus leucovorin,irinotecan,and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol 2004; 22:23-30
  • 9[9]Grothey A,Sargent D.Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil,irinotecan,and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.J Clin Oncol 2005; 23:9441-9442
  • 10[10]Saltz LB,Cox JV,Blanke C,Rosen LS,Fehrenba cher L,Moore MJ,Maroun JA,Ackland SP,Locker PK,Pirotta N,Elfring GL,Miller LL.Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.Irinotecan Study Group.N Engl J Med 2000; 343:905-914

共引文献31

同被引文献33

引证文献10

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部